Compare TWST & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TWST | ERAS |
|---|---|---|
| Founded | 2013 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.4B | 6.3B |
| IPO Year | 2018 | 2021 |
| Metric | TWST | ERAS |
|---|---|---|
| Price | $110.22 | $13.80 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 9 |
| Target Price | ★ $128.92 | $24.11 |
| AVG Volume (30 Days) | 2.3M | ★ 4.8M |
| Earning Date | 11-12-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 36.23 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $459,433,000.00 | N/A |
| Revenue This Year | $21.02 | N/A |
| Revenue Next Year | $18.75 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 22.00 | N/A |
| 52 Week Low | $25.23 | $2.75 |
| 52 Week High | $219.71 | $24.28 |
| Indicator | TWST | ERAS |
|---|---|---|
| Relative Strength Index (RSI) | 38.28 | 43.56 |
| Support Level | $79.90 | $13.18 |
| Resistance Level | $155.44 | $15.71 |
| Average True Range (ATR) | 15.07 | 1.31 |
| MACD | -3.22 | 0.02 |
| Stochastic Oscillator | 18.52 | 18.09 |
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.